Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 12, 2014, Pages 4925-4928

  Zhai, Xu ^a   Li, Shi Jun ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

CDH13 gene; DNA methylation; Individualized chemotherapy; Non small cell lung cancer; RASSF1A gene

Indexed keywords

ANTINEOPLASTIC AGENT; CADHERIN; H-CADHERIN; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; COMPARATIVE STUDY; DNA METHYLATION; DRUG EFFECTS; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; SECONDARY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84904697557     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.12.4925     Document Type: Article

References (14)

1. Blattler A, Farnham PJ (2013). Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem, 288, 34287-94.
2. Jung UL, Hae JS, Ji WS (2012). Promoter Methylation of CDKN2A, RARß, and RASSF1A in Non-Small Cell Lung Carcinoma: Quantitative Evaluation Using Pyrosequencing. Tuberc Respir Dis, 73, 11-21.
3. Linda EC, Thomas J, Prof MT, et al (2009). Molecular predictive and prognostic markers in non-small-cell lung cancer. Lanc Oncol, 10, 1001-10.
4. Milica Kontic, Jelena Stojsic, Dragana Jovanovic, et al (2012). Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathological characteristics of primary non small cell lung carcinoma. Clin Lung Cancer, 13, 297-303.
5. Nunomiya K, Shibata Y, Abe S, et al (2014). Relationship between serum level of lymphatic vessel endothelial hyaluronan receptor-1 and prognosis in patients with lung cancer. J Cancer, 5, 242-7.
6. Pitroda SP, Pashatan M, Logan HL, et al (2014). DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med, 6, 229-42.
7. Qiang L, Junfeng G, Kelong M, et al (2009). RASSF1A, APC, ESR1, ABCB1 and HOXC9, but p16 INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stageInon-small cell lung cancer in China. J Cancer Res Clin Oncol, 135, 1675-84.
8. Shicheng G, Lixing T, Weilin P, et al (2014). Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer. Clin Epig, 1, 229-38.
9. Shin HH, Sey EL, Yu TC, et al (2014). Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small cell lung cancer. Mol Clin Oncol, 2, 252-8.
10. Song Z, Zhang Y (2013). Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib. Mol Clin Oncol, 1, 875-8.
11. Vo T TL, Ta BT, Doan MT, et al (2013). Methylation Profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer. Asian Pac J Cancer Prev, 14, 7713-8.
12. Xinbing S, Na K, Minghua Z, et al (2013). Cotargeting EGFR and autophagy signaling: a novel therapeutic strategy for non-small-cell lung cancer. Mol Clin Oncol, 2, 8-12.
13. Yong QD, Jiang SL, Shui BZ, et al (2013). Effect of 5-aza-2'- deoxycytidine on cell proliferation of non small cell lung cancer cell line A549 cells and expression of the TFPI-2 gene. Asian Pac J Cancer Prev, 14, 4421-6.
14. Zinn RL, Pruitt K, Eguchi S, et al (2007). hTERT is expressed in cancer cell lines despite promoter DNA methylation by preserbation of unmethylated DNA and active chromatin aroud the transcription start site. Cancer Res, 67, 194-201.